Ani Pharmaceuticals Inc Revenue Growth Rates (ANIP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)
 

ANIP's Revenue Growth by Quarter and Year

Ani Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ANIP/growth
https://api.csimarket.com/api/v1/companies/ANIP/fundamentals
https://api.csimarket.com/api/v1/companies/ANIP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ANIP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 290.78
2nd Quarter June 266.04
1st Quarter March 237.46
FY 794.28

ANIPs Annual Revenue
Ani Pharmaceuticals Inc's Revenue in the fiscal year 2025 $ 883.37 millions
Ani Pharmaceuticals Inc's Revenue in the fiscal year 2024 $ 614.38 millions
Ani Pharmaceuticals Inc's Revenue in the fiscal year 2023 $ 486.82 millions
Ani Pharmaceuticals Inc's Revenue in the fiscal year 2022 $ 316.39 millions
Ani Pharmaceuticals Inc's Revenue in the fiscal year 2021 $ 216.14 millions




ANIP Revenue third quarter 2026 Y/Y Growth Comment
Ani Pharmaceuticals Inc reported Revenue improvement of 27.64% year on year in the third quarter 2026, to $ 290.78 millions, this is lower than Ani Pharmaceuticals Inc's recent average Revenue surge of 381.91%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Revenue growth. While Ani Pharmaceuticals Inc' s Revenue rise of 27.64% ranks overall at the positon no. 854 in the third quarter 2026.


ANIP Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 27.64 %
2nd Quarter June 25.86 %
1st Quarter March 20.46 %
FY   -

Financial Statements
Ani Pharmaceuticals Inc's third quarter 2026 Revenue $ 290.78 millions ANIP's Income Statement
Ani Pharmaceuticals Inc's third quarter 2025 Revenue $ 227.81 millions Quarterly ANIP's Income Statement


ANIP Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9.3 %
2nd Quarter June 12.04 %
1st Quarter March -3.89 %
FY (Year on Year)   -


Back to ANIP Growth rate Comparisons >> Back to ANIP Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #180
Overall #854

Revenue Y/Y Growth Statistics
High Average Low
6999.12 % 381.91 % -99.87 %
(Jun 30 2014)   (Jun 30 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #180
Overall #854
Revenue Y/Y Growth Statistics
High Average Low
6999.12 % 381.91 % -99.87 %
(Jun 30 2014)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ani Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
39760.14 % 653.63 % -100 %
(Mar 31 2011)  


ANIP's III. Quarter Q/Q Revenue Comment
Ani Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue increase of 9.3% quarter on quarter, to $ 290.78 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 7.78% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Ani Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 722.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #722
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #722
Revenue Q/Q Growth Statistics
High Average Low
39760.14 % 653.63 % -100 %
(Mar 31 2011)  


ANIP's III. Quarter Q/Q Revenue Comment
Ani Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue increase of 9.3% quarter on quarter, to $ 290.78 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.78% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Ani Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 722.


Ani Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,041.34
Y / Y Revenue Growth (TTM) 25.94 %
Year on Year Revenue Growth Overall Ranking # 438
Seqeuential Revenue Change (TTM) 6.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 1414


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Ani Pharmaceuticals Inc's cumulative twelve months Revenue were $ 1,041 millions, company would post below average annual Revenue growth of 6.44% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Ani Pharmaceuticals Inc's Revenue growth from the 266.04% growth in Jun 30 2026.

In the Healthcare sector 107 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 272 to 438.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 108
Overall # 438

Revenue TTM Y/Y Growth Statistics
High Average Low
4707.96 %
 180.93 %
-99.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 242
S&P 500 # 1414
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Ani Pharmaceuticals Inc's cumulative twelve months Revenue were $ 1,041 millions, company would post below average annual Revenue growth of -99.73% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Ani Pharmaceuticals Inc's Revenue growth from the 266.04% growth in Jun 30 2026.

In the Healthcare sector 107 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 272 to 438.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 108
Overall # 438

Revenue TTM Y/Y Growth Statistics
High Average Low
4707.96 %
180.93 %
-99.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 242
S&P 500 # 1414




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANIP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions


About Ani Pharmaceuticals Inc Revenue Growth Rates (ANIP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ani Pharmaceuticals Inc (CIK 1023024).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001023024-26-000078
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ani Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.